Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- M23-716 Rinvoq PH 3 Alopecia Areata NCT06012240
- M23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No ClinicalTrials.gov identifier reported
- M23-730 - A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Tear Formulation with REFRESH OPTIVE Unit Dose in Patients with Dry Eye Disease No ClinicalTrials.gov identifier reported
- M23-732 - A Study to Assess Adverse Events Change in Disease Activity and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab No ClinicalTrials.gov identifier reported
- M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No ClinicalTrials.gov identifier reported
- M23-889 Ph 1 Single Dose (SAD)-HVs and Asian PK Study NCT05738850
- M23-894 ABBV-932 Ph 2 BPD NCT06605599
- M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No ClinicalTrials.gov identifier reported
- M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No ClinicalTrials.gov identifier reported
- M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No ClinicalTrials.gov identifier reported
- M24-108 - A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No ClinicalTrials.gov identifier reported
- M24-110 - Multicenter Double-Blind Randomized Placebo-controlled Dose-Ranging Phase 2 Active Comparator Study Evaluating the Efficacy and Safety of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines No ClinicalTrials.gov identifier reported
- M24-122 ABBV-303 Ph 1b Dose Escalation Expansion NCT06158958
- M24-144 - A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease No ClinicalTrials.gov identifier reported
- M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No ClinicalTrials.gov identifier reported
- M24-209 - A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion No ClinicalTrials.gov identifier reported
- M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No ClinicalTrials.gov identifier reported
- M24-311 - Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No ClinicalTrials.gov identifier reported
- M24-342 - A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants No ClinicalTrials.gov identifier reported
- M24-425 (Spasticity) Virtual Panel Discussion No ClinicalTrials.gov identifier reported
- M24-427 - Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No ClinicalTrials.gov identifier reported
- M24-465 - Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics Safety and Tolerability of Lutikizumab in Chinese Participants No ClinicalTrials.gov identifier reported
- M24-536 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No ClinicalTrials.gov identifier reported
- M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No ClinicalTrials.gov identifier reported
- M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No ClinicalTrials.gov identifier reported
- M24-704 - A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No ClinicalTrials.gov identifier reported
- M24-708 - Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants No ClinicalTrials.gov identifier reported
- M24-727 - A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No ClinicalTrials.gov identifier reported
- M24-840 - A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder No ClinicalTrials.gov identifier reported
- M24-846 - A Phase 2b Double-Blind, Placebo-Controlled, Adaptive, Dose-Escalation Study to Evaluate the Safety and Efficacy of AGN-151607-DP for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique, in Subjects Undergoing Open Abdominal Ventral Hernia Repair NCT07226791
- M24-885 ABBV-766 Ph 2 PoC Combo study (066 + 981;323; 382) NCT06548542
- M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No ClinicalTrials.gov identifier reported
- M24-922 - A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab No ClinicalTrials.gov identifier reported
- M24-977 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No ClinicalTrials.gov identifier reported
- M25-207 - A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No ClinicalTrials.gov identifier reported
- M25-274 - A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No ClinicalTrials.gov identifier reported
- M25-509 AGN-607 Ph2-3 3L OAB Study 1 No ClinicalTrials.gov identifier reported
- M25-509 AGN-607 Ph2-3 3L OAB Study 1 No ClinicalTrials.gov identifier reported
- M25-526 - A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No ClinicalTrials.gov identifier reported
- M25-966 Nimble Ph 1 TL1A UC DDI Study (n=16) No ClinicalTrials.gov identifier reported
- M-27134-01 No ClinicalTrials.gov identifier reported
- M3541 in Combination With Radiotherapy in Subjects With Solid Tumors No ClinicalTrials.gov identifier reported
- M3gm Ucc-8001 No ClinicalTrials.gov identifier reported
- M6-C 2L No ClinicalTrials.gov identifier reported
- M6-C 2L, M6-C Pas No ClinicalTrials.gov identifier reported
- M6-C 2L, M6-C Pas, Rwe(Sppm) No ClinicalTrials.gov identifier reported
- M6-C Artificial Cervical Disc IDE Post Approval Study NCT04122248
- M6-C Artificial Cervical Disc IDE Post Approval Study NCT04122248
- M6-C Artificial Cervical Disc Two-Level IDE Pivotal Study NCT04982835
- M6-C Artificial Cervical Disc Two-Level IDE Pivotal Study NCT04982835